Pomalyst 2MG, 4MG
Ended Awarded Last action
- Contract number
- 36C24526N0375
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $127,169
Award facts
- Contract value 100% obligated
- $127,169.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company has been awarded a delivery order valued at $127,169.40 for the supply of POMALYST (pomalidomide) in 2 mg and 4 mg formulations to support the Department of Veterans Affairs' Veterans Integrated Service Network 5 (VISN 5). This firm fixed-price contract is issued as a call against Bristol-Myers Squibb's existing Federal Supply Schedule contract (FSS-61-IB: Pharmaceuticals and Drugs) with the VA, which carries a ceiling value of $12.3 billion and extends through April 30, 2029. The delivery order is scheduled for completion by March 6, 2026, with performance of work conducted in Memphis, Tennessee.
POMALYST is a specialty oncology pharmaceutical primarily used in the treatment of multiple myeloma and other hematologic malignancies. This delivery order reflects the VA's ongoing procurement needs for advanced cancer treatments across its healthcare system. Bristol-Myers Squibb, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, specializes in oncology, immunotherapy, and specialized cell therapies and has served as a critical pharmaceutical supplier to the VA through its Federal Supply Schedule contract. The award carries no set-aside designation, consistent with Bristol-Myers Squibb's status as a large manufacturer. This delivery order represents one of more than fifty documented orders the VA has issued to Bristol-Myers Squibb since 2022, demonstrating sustained demand for the company's specialized oncology products within the Veterans Health Administration network.
Quick answers
Who was awarded contract 36C24526N0375?
36C24526N0375 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 26, 2026.
How much is contract 36C24526N0375 worth?
The government has obligated $127,169 on 36C24526N0375.
Is contract 36C24526N0375 an order under another contract?
Yes. 36C24526N0375 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0375 competed?
The extent of competition for 36C24526N0375 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award